Matthew Reilley is an Oncology physician affiliated with University of Virginia. OpenAlex indexes 126 publications with 1,299 citations (h-index 16).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1240 Lee St
Charlottesville, VA 229084000
Telephone
434-924-9333Provider last certified this registry record 12 Oct 2020.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year202522 payments$22,207openpaymentsdata.cms.gov ↗
- Gilead Sciences, Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
32.7%Opioid Agonist10.8%Oxycodone Hcl52%Tramadol Hcl25%Fentanyl23%Part D<11 patientsPhenothiazine8.3%Prochlorperazine Maleate100%Part D≥25 patients+ 4 more classes in this area
Metabolism & gastrointestinal
30.2%Serotonin-3 Receptor Antagonist15.9%Ondansetron Hcl82%Ondansetron Odt18%Part D<11 patientsCorticosteroid5%Prednisone100%Part D≥11 patients+ 3 more classes in this area
Cancer & immunology
12%Kinase inhibitor12%Imatinib Mesylate60%Cabometyx23%Everolimus18%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Prevalence and biological impact of clinically relevant gene fusions in head and neck cancers
npj Precision Oncology
2025 - Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial
Journal of Immunotherapy and Precision Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Charles Landen, MD
University of Virginia
Stephen Caldwell
University of Virginia
James Platts-Mills, MD
University of Virginia
Eric Houpt
University of Virginia
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”